Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(29 sites)

United States

Research Site, La Jolla, California

Research Site, Boston, Massachusetts

Research Site, Hackensack, New Jersey

Research Site, New York, New York

Research Site, Charlotte, North Carolina

Research Site, Winston-Salem, North Carolina

Research Site, Houston, Texas

Research Site, Seattle, Washington

Australia

Research Site, Melbourne

Research Site, Nedlands

Canada

Research Site, Calgary, Alberta

Research Site, Toronto, Ontario

Research Site, Montreal, Quebec

China

Research Site, Hangzhou

Research Site, Shanghai

Denmark

Research Site, København Ø

France

Research Site, Pessac

Research Site, Villejuif

Germany

Research Site, München

Research Site, Ulm

Research Site, Würzburg

Italy

Research Site, Bologna

Research Site, Milan

Japan

Research Site, Chūōku

Research Site, Kashiwa

Spain

Research Site, Barcelona

Research Site, L'Hospitalet de Llobregat

Research Site, Madrid